Conclusion
L. plantarum strains ZF06-1, ZF06-3 and IF2-14 and L. brevis strain
IF2-17 were found able to inhibit DPP-IV and porcine intestinal
α-glucosidase, and displayed good probiotic properties in
vitro. Specific peptide-cleavage and fragmental release in CFS
contribute higher DPP-IV inhibition and bioactivities. Lactobacilli
with DPP-IV and α-glucosidase inhibitory activities may
serve as potential candidates for the management of T2D by
means of their dual ability to slow both inactivation of the
incretin hormones and intestinal absorbance of carbohydrates.
Further investigations into the isolation and
identification of the bioactive components present in CFS of
lactobacilli are therefore warranted. The antihyperglycaemic
potential of these strains should also be further studied in vivo